A study published today in the journal Nature reports that a
viral predator of the cholera bacteria has stolen the functional immune
system of bacteria and is using it against its bacterial host. The study
provides the first evidence that this type of virus, the bacteriophage
("phage" for short), can acquire a wholly functional and adaptive immune
system.
The phage used the stolen immune system to disable -- and thus
overcome -- the cholera bacteria's defense system against phages.
Therefore, the phage can kill the cholera bacteria and multiply to
produce more phage offspring, which can then kill more cholera bacteria.
The study has dramatic implications for phage therapy, which is the use
of phages to treat bacterial diseases. Developing phage therapy is
particularly important because some bacteria, called superbugs, are
resistant to most or all current antibiotics.
Until now, scientists thought phages existed only as primitive
particles of DNA or RNA and therefore lacked the sophistication of an
adaptive immune system, which is a system that can respond rapidly to a
nearly infinite variety of new challenges. Phages are viruses that prey
exclusively on bacteria and each phage is parasitically mated to a
specific type of bacteria. This study focused on a phage that attacks
Vibrio cholerae, the bacterium responsible for cholera epidemics in
humans.
Howard Hughes Medical Institute investigator Andrew Camilli, Ph.D.,
of Tufts University School of Medicine led the research team responsible
for the surprising discovery.
First author Kimberley D. Seed, Ph.D., a postdoctoral fellow in
Camilli's lab, was analyzing DNA sequences of phages taken from stool
samples from patients with cholera in Bangladesh when she identified
genes for a functional immune system previously found only in some
bacteria (and most Archaea, a separate domain of single-celled
microorganisms).
To verify the findings, the researchers used phage lacking the
adaptive immune system to infect a new strain of cholera bacteria that
is naturally resistant to the phage. The phage were unable to adapt to
and kill the cholera strain. They next infected the same strain of
cholera bacteria with phage harboring the immune system, and observed
that the phage rapidly adapted and thus gained the ability to kill the
cholera bacteria. This work demonstrates that the immune system harbored
by the phage is fully functional and adaptive.
"Virtually all bacteria can be infected by phages. About half of the
world's known bacteria have this adaptive immune system, called
CRISPR/Cas, which is used primarily to provide immunity against phages.
Although this immune system was commandeered by the phage, its origin
remains unknown because the cholera bacterium itself currently lacks
this system. What is really remarkable is that the immune system is
being used by the phage to adapt to and overcome the defense systems of
the cholera bacteria. Finding a CRISPR/Cas system in a phage shows that
there is gene flow between the phage and bacteria even for something as
large and complex as the genes for an adaptive immune system," said
Seed.
"The study lends credence to the controversial idea that viruses are
living creatures, and bolsters the possibility of using phage therapy to
treat bacterial infections, especially those that are resistant to
antibiotic treatment," said Camilli, professor of Molecular Biology
& Microbiology at Tufts University School of Medicine and member of
the Molecular Microbiology program faculty at the Sackler School of
Graduate Biomedical Sciences at Tufts University.
Camilli's previous research established that phages are highly
prevalent in stool samples from patients with cholera, implying that
phage therapy is happening naturally and could be made more effective.
In addition, a study published by Camilli in 2008 determined that phage
therapy works in a mouse model of cholera intestinal infection.
The team is currently working on a study to understand precisely how
the phage immune system disables the defense systems of the cholera
bacteria. This new knowledge will be important for understanding whether
the phage's immune system could overcome newly acquired or evolved
phage defense systems of the cholera bacteria, and thus has implications
for designing an effective and stable phage therapy to combat cholera.
Additional authors are David W. Lazinski, Ph.D., senior research
associate in the Camilli lab at Tufts University School of Medicine, and
Stephen B. Calderwood, M.D., Morton N. Swartz, M.D. academy professor
of medicine at Harvard Medical School, and chief, division of infectious
disease and vice-chair, department of medicine at Massachusetts General
Hospital.
Research reported in this publication was supported by the National
Institute of Allergies and Infectious Diseases of the National
Institutes of Health under award numbers R01AI55058, R01AI045746, and
R01AI058935.
Journal Reference:
- Kimberley D. Seed, David W. Lazinski, Stephen B. Calderwood, Andrew Camilli. A bacteriophage encodes its own CRISPR/Cas adaptive response to evade host innate immunity. Nature, 2013; 494 (7438): 489 DOI: 10.1038/nature11927
Courtesy: ScienceDaily
No comments:
Post a Comment